Armand Neukermans - Durect Independent Director
| DRRX Stock | USD 0.97 0.01 1.04% |
Director
Dr. Armand P. Neukermans, Ph.D., is an Independent Director of DURECT Corporationrationration, since March 2001. Dr. Neukermans founded Xros, Inc. in December 1996. Xros was acquired by and became a division of Nortel Networks in March 2000. Throughout and until June 2002, Dr. Neukermans held the position of Chairman and Chief Technical Officer at Xros. In October 1993, Dr. Neukermans founded Adagio Associates, a consulting firm in the area of instrumentation, metrology and microfabrication and currently serves as its President. From 1992 to 1993, Dr. Neukermans was Vice President, Systems Development at Teknekron TSDC. Between 1985 and 1992, Dr. Neukermans held various positions at Tencor Instruments including Vice President and Chief Technical Officer. From 1973 to 1985, Dr. Neukermans held various positions at Hewlett Packard Company, HP Labs, including Department Manager. Dr. Neukermans holds an Engineers Degree in Mechanical and Electrical Engineering from Louvain University, an M.S. in Electrical Engineering from Arizona State University and a Ph.D. in Applied Physics from Stanford University. Dr. Neukermans was named Silicon Valley Inventor of the Year in 2001. Dr. Neukermans engineering and technical expertise and general industrial experience as relates to executive management and business operations are among the qualifications he brings to the Board and his service as a Director of the Company. since 2001.
| Age | 73 |
| Tenure | 23 years |
| Address | 10260 Bubb Road, Cupertino, CA, United States, 95014-4166 |
| Phone | 408 777 1417 |
| Web | https://www.durect.com |
Durect Management Efficiency
The company has return on total asset (ROA) of (0.4379) % which means that it has lost $0.4379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3893) %, meaning that it created substantial loss on money invested by shareholders. Durect's management efficiency ratios could be used to measure how well Durect manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.74 in 2024. Return On Capital Employed is likely to rise to -1.93 in 2024. At this time, Durect's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 13.2 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 121.6 K in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Pascal Weerts | Redhill Biopharma | N/A | |
| Patrick Heron | Collegium Pharmaceutical | 44 | |
| Kenneth Widder | Evoke Pharma | 65 | |
| Ken Widder | Evoke Pharma | 65 | |
| Santo Costa | Aquestive Therapeutics | 73 | |
| Gregory Brown | Aquestive Therapeutics | 64 | |
| Garheng Kong | Alimera Sciences | 42 | |
| Floyd Bloom | Alkermes Plc | 80 | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Garen Bohlin | Collegium Pharmaceutical | 70 | |
| Julie McHugh | Ironwood Pharmaceuticals | 60 | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Brian Halak | Alimera Sciences | 45 | |
| Danny Biran | Taro Pharmaceutical Industries | 71 | |
| Sharon Barbari | Sonoma Pharmaceuticals | 61 | |
| Mark Brooks | Alimera Sciences | 50 | |
| Douglas Williams | Ironwood Pharmaceuticals | 59 | |
| Sudhir Valia | Taro Pharmaceutical Industries | 63 | |
| Matt Roache | Ironwood Pharmaceuticals | N/A | |
| Nancy Snyderman | Alkermes Plc | 66 | |
| James Largent | Alimera Sciences | 67 | |
Management Performance
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.44 |
Durect Leadership Team
Elected by the shareholders, the Durect's board of directors comprises two types of representatives: Durect inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Durect. The board's role is to monitor Durect's management team and ensure that shareholders' interests are well served. Durect's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Durect's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Simon Benito, Independent Director | ||
| Gail Farfel, Director | ||
| James DVM, CEO, CoFounder | ||
| Norman MD, Chief Officer | ||
| Keith MBA, Commercial Development | ||
| David Hoffmann, Lead Independent Director | ||
| Terrence Blaschke, Independent Director | ||
| Timothy MBA, CFO Secretary | ||
| WeiQi MD, Executive Scientist | ||
| Judy Joice, Sr. VP of Operations and Corporate Quality Assurance | ||
| Michael Arenberg, CFO | ||
| Jian MBA, Corporate Finance | ||
| Su Yum, Executive Officer | ||
| James Brown, President CEO, Director | ||
| Armand Neukermans, Independent Director | ||
| Felix Theeuwes, Chairman of the Board, Chief Scientific Officer | ||
| Andrew Miksztal, VP Scientist | ||
| Judith Robertson, Director | ||
| Jon Saxe, Independent Director | ||
| Jay Shepard, Director | ||
| Myriam Theeuwes, Senior Vice President - Clinical Development | ||
| Matthew Hogan, CFO | ||
| Steve JD, VP Counsel |
Durect Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Durect a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (2.34) % | ||||
| Current Valuation | 20.85 M | ||||
| Shares Outstanding | 31.04 M | ||||
| Shares Owned By Insiders | 5.97 % | ||||
| Shares Owned By Institutions | 22.56 % | ||||
| Number Of Shares Shorted | 927.54 K | ||||
| Price To Earning | (3.09) X | ||||
| Price To Book | 1.62 X |
Pair Trading with Durect
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Durect position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Durect will appreciate offsetting losses from the drop in the long position's value.Moving against Durect Stock
| 0.6 | PDEX | Pro Dex Earnings Call Today | PairCorr |
| 0.44 | ZJYL | JIN MEDICAL INTERNATIONAL | PairCorr |
The ability to find closely correlated positions to Durect could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Durect when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Durect - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Durect to buy it.
The correlation of Durect is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Durect moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Durect moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Durect can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Durect. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Durect Stock please use our How to Invest in Durect guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Durect Stock analysis
When running Durect's price analysis, check to measure Durect's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Durect is operating at the current time. Most of Durect's value examination focuses on studying past and present price action to predict the probability of Durect's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Durect's price. Additionally, you may evaluate how the addition of Durect to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Durect's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Durect. If investors know Durect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Durect listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Revenue Per Share 0.326 | Quarterly Revenue Growth (0.20) | Return On Assets (0.44) | Return On Equity (1.39) |
The market value of Durect is measured differently than its book value, which is the value of Durect that is recorded on the company's balance sheet. Investors also form their own opinion of Durect's value that differs from its market value or its book value, called intrinsic value, which is Durect's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Durect's market value can be influenced by many factors that don't directly affect Durect's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Durect's value and its price as these two are different measures arrived at by different means. Investors typically determine if Durect is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Durect's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.